中华放射医学与防护杂志
中華放射醫學與防護雜誌
중화방사의학여방호잡지
Chinese Journal of Radiological Medicine and Protection
2012年
3期
304-307
,共4页
柏朋刚%李奇欣%陈开强%张秀春%王雅智%黄星武
柏朋剛%李奇訢%陳開彊%張秀春%王雅智%黃星武
백붕강%리기흔%진개강%장수춘%왕아지%황성무
COMPASS系统%容积旋转调强%剂量验证
COMPASS繫統%容積鏇轉調彊%劑量驗證
COMPASS계통%용적선전조강%제량험증
COMPASS system%Volumetric modulated arc therapy%Dosimetric verification
目的 探讨COMPASS三维剂量验证系统在鼻咽癌容积旋转调强剂量验证中的应用.方法 选取8例鼻咽癌病例在Masterplan治疗计划系统中进行旋转调强计划设计,然后将治疗计划分别传输至COMPASS系统和控制加速器运行的MOSAIQ网络上.比较计划系统计算结果和COMPASS实际测量结果差异的主要指标,如靶区的平均剂量(Dmean)、95％体积剂量(D95％)和γ值,脊髓、脑干的Dmean和D1％左右腮腺的Dmean、V30.结果 计划系统计算结果和COMPASS实际测量的结果二者在靶区的γ通过率均＞95％,各个靶区的D95%平均偏差大多＜3％,各个靶区Dmean的偏差平均值在1％以内.脊髓和脑干的D1％的平均偏差分别为(4.3±3.0)％和(5.9±2.9)％,二者Dmean的平均偏差分别为(5.3±3.0)％和(8.0±3.5)％.COMPASS测量的脊髓和脑干的剂量都比计划系统计算的结果小.左右腮腺Dmean差异的平均值分别为(6.1±3.1)％、(4.7±4.4)％,V30的差异分别为(9.4±7.5)％和(9.4±9.9)％.结论 COMPASS三维剂量验证系统是容积旋转调强剂量验证的一个非常理想的工具,可以快速、直观地分析出靶区和正常器官理论和实际照射情况下的差异.
目的 探討COMPASS三維劑量驗證繫統在鼻嚥癌容積鏇轉調彊劑量驗證中的應用.方法 選取8例鼻嚥癌病例在Masterplan治療計劃繫統中進行鏇轉調彊計劃設計,然後將治療計劃分彆傳輸至COMPASS繫統和控製加速器運行的MOSAIQ網絡上.比較計劃繫統計算結果和COMPASS實際測量結果差異的主要指標,如靶區的平均劑量(Dmean)、95％體積劑量(D95％)和γ值,脊髓、腦榦的Dmean和D1％左右腮腺的Dmean、V30.結果 計劃繫統計算結果和COMPASS實際測量的結果二者在靶區的γ通過率均＞95％,各箇靶區的D95%平均偏差大多＜3％,各箇靶區Dmean的偏差平均值在1％以內.脊髓和腦榦的D1％的平均偏差分彆為(4.3±3.0)％和(5.9±2.9)％,二者Dmean的平均偏差分彆為(5.3±3.0)％和(8.0±3.5)％.COMPASS測量的脊髓和腦榦的劑量都比計劃繫統計算的結果小.左右腮腺Dmean差異的平均值分彆為(6.1±3.1)％、(4.7±4.4)％,V30的差異分彆為(9.4±7.5)％和(9.4±9.9)％.結論 COMPASS三維劑量驗證繫統是容積鏇轉調彊劑量驗證的一箇非常理想的工具,可以快速、直觀地分析齣靶區和正常器官理論和實際照射情況下的差異.
목적 탐토COMPASS삼유제량험증계통재비인암용적선전조강제량험증중적응용.방법 선취8례비인암병례재Masterplan치료계화계통중진행선전조강계화설계,연후장치료계화분별전수지COMPASS계통화공제가속기운행적MOSAIQ망락상.비교계화계통계산결과화COMPASS실제측량결과차이적주요지표,여파구적평균제량(Dmean)、95％체적제량(D95％)화γ치,척수、뇌간적Dmean화D1％좌우시선적Dmean、V30.결과 계화계통계산결과화COMPASS실제측량적결과이자재파구적γ통과솔균＞95％,각개파구적D95%평균편차대다＜3％,각개파구Dmean적편차평균치재1％이내.척수화뇌간적D1％적평균편차분별위(4.3±3.0)％화(5.9±2.9)％,이자Dmean적평균편차분별위(5.3±3.0)％화(8.0±3.5)％.COMPASS측량적척수화뇌간적제량도비계화계통계산적결과소.좌우시선Dmean차이적평균치분별위(6.1±3.1)％、(4.7±4.4)％,V30적차이분별위(9.4±7.5)％화(9.4±9.9)％.결론 COMPASS삼유제량험증계통시용적선전조강제량험증적일개비상이상적공구,가이쾌속、직관지분석출파구화정상기관이론화실제조사정황하적차이.
Objective To investigate the dosimetric performance of COMPASS system,a novel 3D quality assurance system for the verification of nasopharyngeal carcinoma volumetric modulated therapy (VMAT) treatment plan.Methods Eight VMAT treatment plans of nasopharyngeal carcinoma patients were performed with MasterPlan,a treatment planning system (TPS),and then these treatment plans were sent to the COMPASS and MOSAIQ system,a coherent control system,respectively.Comparison of the COMPASS reconstructed dose versus TPS dose was conducted by using the dose volume-based indices:dose received by 95％ volume of target ( D95％ ),mean dose ( Dmean ) and γ pass rate,dose to the 1％ of the spinal cord and brain stem volume ( D1％ ),mean dose of leaf and right parotid ( Dmean ),and the volume received 30 Gy for left and right parotid (V30).COMPASS can reconstruct dose with the real measured delivery fluence after detector commissioning.Results The average dose difference for the target volumes was within 1％,the difference for D95 was within 3％ for most treatment plans,and the γ pass rate was higher than 95％ for all target volumes.The average differences for the D1％ values of spinal cord and brain stem were ( 4.3 ± 3.0) ％ and ( 5.9± 2.9 ) ％ respectively,and the average differences for the Dmean values of spinal cord and brain stem were ( 5.3 ± 3.0 ) ％ and ( 8.0 ± 3.5 ) ％ respectively.In general the COMPASS measured doses were all smaller than the TPS calculated doses for these two organs.The average differences of the Dmean values of the left and right parotids were( 6.1± 3.1 ) ％ and ( 4.7 ± 4.4 ) ％ respectively,and the average differences of the V30 values of the left and right parotids were (9.4 ± 7.5 ) ％ and (9.4 ± 9.9)％ respectively.Conclusions An ideal tool for the VMAT verification,the patient anatomy based COMPASS 3D dose verification system can check the dose difference between the real delivery and TPS calculation directly for each individual organ,either target volumes or critical organs.
